Clarification3 Oct 2026, 06:40 pm
Transgene Biotek: Statement of Deviation/Variation Not Applicable for Q2 FY27
AI Summary
Transgene Biotek Ltd has filed a Statement of Deviation or Variation for the quarter ended September 30, 2026. The company clarified that as there were no public issues, rights issues, or preferential issues during the reporting quarter, the statement of deviation or variation is not applicable. They also noted an inability to file a NIL entry in the XBRL mode.
Key Highlights
- Statement of Deviation/Variation filed for Q2 FY27.
- No public, rights, or preferential issues occurred in the quarter.
- The statement of deviation/variation is therefore not applicable.
- XBRL filing limitation prevented NIL entry submission.
Price Impact
More from TRABI